The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISA 2020 | ANDROMEDA study: updated safety run-in results
The Phase III ANDROMEDA (NCT03201965) study investigated subcutaneous daratumumab in combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD) for patients with newly-diagnosed light-chain (AL) amyloidosis. In this video, Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, discusses the updated safety run-in results of the ANDROMEDA study. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
